The Ethical and Scientific Shortcomings of Current Monotherapy Epilepsy Trials in Newly Diagnosed Patients

Epilepsy and Behavior

Volumn 2, Issue 3, 2001, Pages 193-200

  Karlawish, Jason H T ^a   French, Jacqueline ^a  

^a NONE

Author keywords

Epilepsy; clinical trials; research ethics; placebo controls

Indexed keywords

EID: 0000581604     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1006/ebeh.2001.0197     Document Type: Article

References (33)

1. Fried C. Medical experimentation: personal integrity and social policy. 1974;North-Holland, Amsterdam.
2. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 317:1987;141-145.
3. Rosenberg W, Sackett D. On the need for evidence-based medicine. Therapie. 51:1996;212-217.
4. Chadwick D, Anhut H, Greiner M. International Gabapentin Monotherapy Study Group 945-77. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 51:1998;1282-1288.
5. Anonymous. The Nuremberg code. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Vol. 2. Washington, DC, U.S. Govt Printing Office, 1949: 181-2.
6. JAMA. 277:1997;925-926.
7. Ficker D. Sudden unexplained death and injury in epilepsy. Epilepsia. 41:2000;S7-12.
8. Cockerell O. The mortality of epilepsy. Curr Opin Neurol. 9:1996;93-96.
9. Kwan P, Brodie M J. Early identification of refractory epilepsy. N Engl J Med. 342:2000;314-319.
10. Brodie M, Richens A, Yuen A. Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 345:1995;476-479.
11. Mattson R H, Cramer J A, Collins J F. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 313:1985;145-151.
12. Chadwick D. Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet. 354:1999;13-19.
13. Fed Reg. 56:1991;28003-28032.
14. Anonymous. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. Fed Reg. 44:1979;23192-23197.
15. Hauser W A, Rich S S, Lee J R, Annegers J F, Anderson V E. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med. 338:1998;429-434.
16. Shinnar S, Berg A T, O'Dell C, Newstein D, Moshe S L, Hauser W A. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol. 48:2000;140-147.
17. Weijer C. The IRB's role in assessing the generalizability of non-NIH funded clinical trials. IRB: A Rev Hum Subj Res. 20:1998;1-5.
18. World Medical Association Declaration of Helsinki, Ethical principles for medical research involving human subjects, World Medical Association, 2000, http://www.wma.net/policy .
19. Freedman B, Fuks A, Weijer C. Demarcating research and treatment: a systematic approach for the analysis of the ethics of clinical research. Clin Res. 40:1992;653-660.
20. Freedman B. Scientific value and validity as ethical requirements for research: a proposed explication. IRB: A Rev Hum Subj Res. 9:1987;7-10.
21. Gilliam F, Vazquez B, Sackellares J. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 38:1998;294-300.
22. Schachter S, Vazquez B, Fisher. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 52:1999;732-737.
23. Appelbaum P S, Grisso T, Frank E, O'Donnell S, Kupfer D J. Competence of depressed patients for consent to research. Am J Psychiatry. 156:1999;1380-1384.
24. Kass N E, Sugarman J, Faden R, Schoch-Spana M. Trust: the fragile foundation of contemporary biomedical research. Hastings Cent Rep. 26:1996;25-29.
25. Sugarman J, Kass N E, Goodman S N, Perentesis P, Fernandes P, Faden R R. What patients say about medical research. IRB: A Rev Hum Subj Res. 20:1998;1-7.
26. Leber P D. Hazards of inference: the active control investigation. Epilepsia. 30:1989;S57-63.
27. Temple R, Ellenberg S S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med. 133:2000;455-463.
28. N Engl J Med. 337:1997;1124-1130.
29. Lancet. 354:1999;716-722.
30. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 11:1997;S10-21.
31. U. S. Food and Drug Administration Office of Special Health Issues, Vol, 1999;, 1999.
32. Fried S. Bitter pills: inside the hazardous world of legal drugs. 1998;Bantam Books, New York.
33. Epstein S. Impure science: AIDS, activism, and the politics of knowledge. 1996;Univ of California Press, Berkeley.